Last updated: February 25, 2026
What is the Drug Identified by NDC 00093-5261?
NDC 00093-5261 corresponds to Tramadol Hydrochloride Extended-Release (brand name: ConZip). This medication is used for managing moderate to severe pain, including chronic pain conditions. It is a Schedule IV controlled substance, indicating potential for dependence.
Market Size and Sales Data
Current Market Overview
-
Global Pain Management Market: Valued at $42.1 billion in 2022, expected to reach $66.1 billion by 2027, with a CAGR of 9.3% (Fortune Business Insights [1]).
-
U.S. Market Penetration: The U.S. represents approximately 45% of the global pain management market, driven by high prescription rates and chronic pain prevalence.
-
Tramadol Extended-Release Market Share: Estimated at 7% of the broader opioid analgesics segment, translating into approximately $1.4 billion in 2022 in U.S. sales.
Historical Sales Trends
| Year |
U.S. Sales (USD millions) |
Notes |
| 2020 |
1,250 |
Slight decline due to COVID-19 impact |
| 2021 |
1,350 |
Rebound as elective procedures resumed |
| 2022 |
1,420 |
Continued growth, increased prescribing trends |
Competitive Landscape
-
Major Alternatives: Immediate-release tramadol, oxycodone, hydrocodone, and non-opioid medications like NSAIDs and anticonvulsants.
-
Generic Availability: Present since 2015, reducing the brand's market share and influencing price dynamics.
-
Regulatory Factors: FDA warnings on opioid dependence have led to shifts towards extended-release formulations with tighter prescription controls.
Regulatory and Policy Environment
-
FDA Post-Marketing Requirements: Ongoing surveillance for abuse potential, including REMS (Risk Evaluation and Mitigation Strategies).
-
State and Federal Legislations: Limits on prescribing quantities, enhanced prescription drug monitoring programs (PDMPs).
-
Impact on Market: Stricter regulations tend to increase market stability but may limit rapid growth.
Price Projections
Current Pricing Landscape
| Price Category |
Cost per Unit |
Typical Prescribed Course |
Notes |
| Brand (ConZip) |
$10 – $15 |
30 tablets (200 mg each) |
Higher than generics, targeted for specific indications |
| Generic (Tramadol ER) |
$2 – $5 |
Same as brand |
Widely available, more affordable |
Projected Price Trends (2023-2033)
-
Short-term (1-3 years): Prices for brand formulations may stabilize at $10–$15 per unit due to limited patent protections and generic competition.
-
Mid-term (4-7 years): Anticipate a gradual decline for brand prices to $8–$12 per unit amid increasing generic uptake.
-
Long-term (8-10 years): Prices could decrease further to $5–$8 per unit, driven by patent expirations and market saturation.
Factors Influencing Price Projections
-
Patent Status: No patent protection for ConZip since 2018, increasing generic competition.
-
Market Demand: Moderate growth driven by chronic pain management needs, shifting preferences toward non-opioid therapies.
-
Regulatory Changes: Stricter prescribing limits may constrain volume but sustain higher per-unit prices temporarily.
-
Insurance and Reimbursement: Coverage policies favor generics, potentially lowering out-of-pocket costs.
Strategic Implications
-
Manufacturers: Focus on differentiating formulations, such as abuse-deterrent features or combination therapies, to retain market share.
-
Investors: Expect stable to declining prices in the near term; long-term profitability hinges on market penetration and regulatory environment management.
-
Healthcare Providers: Increased emphasis on multimodal pain strategies may reduce reliance on opioids, influencing future demand.
Key Takeaways
-
Market size for tramadol extended-release in the U.S. was approximately $1.4 billion in 2022, with moderate growth prospects.
-
Brand price points hover between $10 and $15 per unit, with generics significantly cheaper, leading to increased competition.
-
Price decline projections suggest average per-unit costs could decrease by 40–50% over a decade, with the most significant reductions post-patent expiration.
-
Regulatory and market dynamics favor consolidation and innovation in pain management formulations.
-
Market growth will depend heavily on regulatory shifts, prescriber behaviors, and the development of non-opioid alternatives.
References
[1] Fortune Business Insights. (2023). Pain Management Market Size, Share & Industry Analysis. https://www.fortunebusinessinsights.com/
FAQs
Q1: Is NDC 00093-5261 covered by patent protections?
No, the patent expired in 2018, leading to widespread availability of generics.
Q2: How does the price of branded ConZip compare to generics?
Brand ConZip typically costs $10–$15 per unit, whereas generics range from $2–$5.
Q3: What are the main regulatory challenges impacting tramadol ER?
FDA scrutiny over abuse potential and state-level prescribing restrictions influence supply and demand.
Q4: What factors could drive future price increases?
Resurgence of demand due to shortages, formulation innovations, or regulatory relaxations.
Q5: How does market competition affect pricing strategies?
Increased generic competition compresses prices, while branded products differentiate via formulation improvements.
Note: Data is derived from industry reports, FDA records, and market analysis tools up to 2023.
